Prévost (CA)
{name}
{subtitle}
AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)
city
~10 mi. (Saint-Jérôme, Canada, +3 more cities)
facility
Centre Intégré de Santé et de Services Sociaux des Laurentides (Hôpital Régional de St-Jérôme)
condition
Non-Small Cell Lung Carcinoma
drug
AB-16B5, +1 more drug
drug type
chemotherapy, +1 more type
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
city
~37 mi. (Laval, Canada, +240 more cities)
facility
Hopital de la Cite-de-la-Sante
condition
Endometrial Adenocarcinoma, +5 more conditions
drug
carboplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
city
~37 mi. (Laval, Canada, +100 more cities)
facility
City of Health Hospital at Laval (Cité de la Santé de Laval)
condition
Fallopian Tube Adenocarcinoma, +14 more conditions
drug
carboplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
city
~37 mi. (Laval, Canada, +105 more cities)
facility
Hopital Cite de la Sante de Laval ( Site 0203)
condition
Colorectal Adenocarcinoma
drug
bevacizumab, +1 more drug
drug type
targeted therapy
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
city
~41 mi. (Kirkland, Canada, +23 more cities)
facility
Merck Canada
condition
Prostate Adenocarcinoma, +1 more condition
drug
abiraterone, +9 more drugs
drug type
chemotherapy, +3 more types
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
city
~46 mi. (Montréal, Canada, +128 more cities)
facility
Hopital Maisonneuve-Rosemont
condition
Multiple Myeloma
drug
bortezomib, +5 more drugs
drug type
cellular therapy, +4 more types
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
city
~46 mi. (Montréal, Canada, +226 more cities)
facility
McGill University Health Centre
biomarker
EGFR Exon 19 Deletion, +1 more biomarker
condition
Non-Squamous Non-Small Cell Lung Carcinoma
drug
amivantamab, +3 more drugs
drug type
chemotherapy, +1 more type
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~46 mi. (Montréal, Canada, +247 more cities)
facility
Centre Hospitalier de l'Université de Montréal-Breast Cancer
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types